Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
Positive single dose AB-729 data in chronic hepatitis B subjects supports further clinical developmentFirst multiple dose cohort results expected in second […]